Phase 2
Completed N=15
Memantine Augmentation in Obsessive-Compulsive Disorder
Source: ClinicalTrials.gov NCT00264238 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks) — 23.8; 30; 13.0; 28.8 units on a scale
Summary
The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks) |
23.8; 30; 13.0; 28.8 | — |
| SECONDARY Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to End of Treatment (12 Weeks) |
11.8; 14.9; 5.0; 14.6 | — |
Eligibility Criteria
Inclusion Criteria
- at least 18 years of age
- suffering from OCD
- Y-BOCS score of 18 or greater
- taking a therapeutic dose of an anti-OCD medication specified in the protocol
Exclusion Criteria
- diagnosed with a mental disorder other than OCD
- taking tiagabine or pregabalin
- having had a previous trial of memantine
- receiving therapy for OCD
- substance abuse in the last 6 months
- personality disorders sufficiently severe to interfere with study participation
Data sourced from ClinicalTrials.gov (NCT00264238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.